Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Author(s):
Bonaca, M.P.; Nault, P.; Giugliano, R.P.; Keech, A.C.; Pineda, A.L.; Kanevsky, E.; Kuder, J.; Murphy, S.A.; Jukema, J.W. (0000-0002-3246-8359); Lewis, B.S.; Tokgozoglu, L.; Somaratne, R.; Sever, P.S.; Pedersen, T.R.; Sabatine, M.S.
Published
2018
Publication type
Article / Letter to editor
amputationatherosclerosischolesterol, LDLevolocumabintermittent claudicationPCSK9 protein, humanperipheral arterial disease
Date issued
2018-01-23
Language
English
Is part of
Circulation (2018), Vol. 137, no. 4, p. 338-350
hdl
1887/87089
doi
10.1161/CIRCULATIONAHA.117.032235